Related references
Note: Only part of the references are listed.Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes
Dennis Kim et al.
DIABETES CARE (2007)
Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study
A. J. Garber et al.
DIABETES OBESITY & METABOLISM (2007)
Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes
J. Rosenstock et al.
DIABETES OBESITY & METABOLISM (2007)
The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes
Daniel J. Drucker et al.
LANCET (2006)
Glucagon-like peptide-1: From extract to agent. The Claude Bernard Lecture, 2005
JJ Holst
DIABETOLOGIA (2006)
Costimulation blockade of both inducible costimulator and CD40 ligand induces dominant tolerance to islet allografts and prevents spontaneous autoimmune diabetes in the NOD mouse
SA Nanji et al.
DIABETES (2006)
Pioglitazone - A review of its use in type 2 diabetes mellitus
J Waugh et al.
DRUGS (2006)
The effects of orlistat in patients with diabetes: improvement in glycaemic control and weight loss
R Rowe et al.
CURRENT MEDICAL RESEARCH AND OPINION (2005)
Severe hypoglycaemia post-gastric bypass requiring partial pancreatectomy: evidence for inappropriate insulin secretion and pancreatic islet hyperplasia
ME Patti et al.
DIABETOLOGIA (2005)
New sources of pancreatic β-cells
S Bonner-Weir et al.
NATURE BIOTECHNOLOGY (2005)
Glucagon-like peptide-1 protects beta cells from cytokine-induced apoptosis and necrosis: role of protein kinase B
L Li et al.
DIABETOLOGIA (2005)
Dose-response for glycaemic and metabolic changes 28 days after single injection of long-acting release exenatide in diabetic fatty Zucker rats
BR Gedulin et al.
DIABETOLOGIA (2005)
PPARs: therapeutic targets for metabolic disease
JP Berger et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2005)
Improvement of glucose tolerance in Zucker diabetic fatty rats by long-term treatment with the dipeptidyl peptidase inhibitor P32/98: comparison with and combination with rosiglitazone
E Wargent et al.
DIABETES OBESITY & METABOLISM (2005)
The dual PPARα/γ agonist, ragaglitazar, improves insulin sensitivity and metabolic profile equally with pioglitazone in diabetic and dietary obese ZDF rats
LC Pickavance et al.
BRITISH JOURNAL OF PHARMACOLOGY (2005)
One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and α- and β-cell function and reduces endogenous glucose release in patients with type 2 diabetes
KB Degn et al.
DIABETES (2004)
Minireview: Glucagon-like peptides regulate cell proliferation and apoptosis in the pancreas, gut, and central nervous system
PL Brubaker et al.
ENDOCRINOLOGY (2004)
GLP-1 derivative liraglutide in rats with β-cell deficiencies:: influence of metabolic state on β-cell mass dynamics
J Sturis et al.
BRITISH JOURNAL OF PHARMACOLOGY (2003)
Differential influences of peroxisonte proliferator-activated receptorsγ and -α on food intake and energy homeostasis
PJ Larsen et al.
DIABETES (2003)
Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus
T Vilsboll et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2003)
Dual PPARα/γ activation provides enhanced improvement of insulin sensitivity and glycemic control in ZDF rats
CL Brand et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2003)
The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men
H Agerso et al.
DIABETOLOGIA (2002)
Desensitization of sulphonylurea- and nutrient-induced insulin secretion following prolonged treatment with glibenclamide
AJ Ball et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2000)
Rosiglitazone prevents the onset of hyperglycaemia and proteinuria in the Zucker diabetic fatty rat
SA Smith et al.
DIABETES OBESITY & METABOLISM (2000)
Profiling of Zucker diabetic fatty rats in their progression to the overt diabetic state
GJ Etgen et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2000)
A descriptive study of weight loss maintenance: 6 and 15 year follow-up of initially overweight adults
S Sarlio-Lahteenkorva et al.
INTERNATIONAL JOURNAL OF OBESITY (2000)
Share Paper
